Imunon, Inc.
News
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
Globe Newswire September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline...\n more…
IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
Globe Newswire September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline...\n more…
IMUNON to Host R&D Day on September 18th
Globe Newswire R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts...\n more…
HC Wainwright Analysts Lift Earnings Estimates for Imunon, Inc. (NASDAQ:IMNN)
Ticker Report Imunon, Inc. (NASDAQ:IMNN - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for shares of Imunon in a research note issued on Thursday, August...\n more…